The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.
 
Timothy A. Yap
Consulting or Advisory Role - Aduro Biotech; Almac Diagnostics; AstraZeneca; Atrin Pharmaceuticals; Axiom Biotechnologies; Bayer; Bristol-Myers Squibb; Calithera Biosciences; Clovis Oncology; Cybrexa Therapeutics; EMD Serono; F-Star; Guidepoint Global; I-Mab; Ignyta; Janssen; Merck; Pfizer; Repare Therapeutics; Roche; Rubius Therapeutics; Schrodinger; Seagen; Varian Medical Systems; Zai Lab
Research Funding - Artios (Inst); AstraZeneca (Inst); Bayer (Inst); Clovis Oncology (Inst); Constellation Pharmaceuticals (Inst); Cyteir (Inst); EMD Serono (Inst); F-Star (Inst); Forbius (Inst); Genentech (Inst); GlaxoSmithKline (Inst); ImmuneSensor Therapeutics (Inst); Ipsen (Inst); Jounce Therapeutics (Inst); Karyopharm Therapeutics (Inst); Kyowa Hakko Kirin (Inst); Lilly (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Repare Therapeutics (Inst); Ribon Therapeutics (Inst); Sanofi (Inst); Scholar Rock (Inst); Seagen (Inst); Tesaro (Inst); Vertex (Inst)
 
Ecaterina Elena Dumbrava
Consulting or Advisory Role - Bolt Biotherapeutics
 
Jordi Rodon Ahnert
Consulting or Advisory Role - Ellipses Pharma; Ionctura; Kelun; Lilly; Merck Sharp & Dohme; Molecular Partners; Novartis; NovellusDx; Orion; Peptomyc; Pfizer; Roche/Genentech; SERVIER; Spectrum Pharmaceuticals
Research Funding - Bayer; BioAtla; Blueprint Medicines; CytomX Therapeutics; Genmab; GlaxoSmithKline; Ipsen; Kelun; Novartis; Pfizer; Spectrum Pharmaceuticals; Symphogen; Takeda/Millennium; Tocagen
Travel, Accommodations, Expenses - Cancer Core Europe; Department of Defense; ESMO; Huntsman Cancer Institute; Karolinska Cancer Institute; King Abdullah International Medical Research Center; Louisiana State University; Molecular Partners
Other Relationship - Chinese University of Hong Kong; Elsevier; European Journal of Cancer; GlaxoSmithKline; SOLTI; Vall d'Hebron University Hospital Institute of Oncology
 
David S. Hong
Stock and Other Ownership Interests - MolecularMatch; OncoResponse; Presagia
Consulting or Advisory Role - Acuta; Adaptimmune; Alphasights; Amgen; Axiom Biotechnologies; Baxter; Bayer; Boxer Capital; COG; EcoR1 Capital; Genentech; Gerson Lehrman Group; GroupH; GroupH; Guidepoint Global; H.C. Wainwright & Co.; HCW Precision; Infinity Pharmaceuticals; Infinity Pharmaceuticals; Janssen; Medscape; Merrimack; Numab; Pfizer; Prime Oncology; Seagen; ST Cube; Takeda; Tavistock Life Sciences; Trieza Therapeutics; WebMD; WebMD
Research Funding - Abbvie (Inst); Adaptimmune (Inst); Aldai Norte (Inst); Amgen (Inst); AstraZeneca (Inst); Bayer (Inst); BMS (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Erasca, Inc (Inst); Fate Therapeutics (Inst); Genentech (Inst); Genmab (Inst); Ignyta (Inst); Infinity Pharmaceuticals (Inst); Kite, a Gilead company (Inst); Kyowa (Inst); Lilly (Inst); Loxo (Inst); MedImmune (Inst); Merck (Inst); Mirati Therapeutics (Inst); miRNA Therapeutics (Inst); Molecular Templates (Inst); Mologen (Inst); National Cancer Institute (Inst); Navire (Inst); Novartis (Inst); Numab (Inst); Pfizer (Inst); Seagen (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Verastem (Inst); VM Pharma (Inst)
Travel, Accommodations, Expenses - AACR; ASCO; Bayer Schering Pharma; Genmab; Loxo; miRNA Therapeutics; Society for Immunotherapy of Cancer
 
Shubham Pant
Honoraria - 4D Pharma
Consulting or Advisory Role - TYME; Xencor; Zymeworks
Research Funding - ArQule (Inst); Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Five Prime Therapeutics (Inst); GlaxoSmithKline (Inst); Ipsen (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Novartis (Inst); Onco Response (Inst); RedHill Biopharma (Inst); Rgenix (Inst); Sanofi/Aventis (Inst); Xencor (Inst)
 
Daniel D. Karp
No Relationships to Disclose
 
Sarina Anne Anne Piha-Paul
Consulting or Advisory Role - Merck
Research Funding - Abbvie (Inst); ABM (Inst); Acepodia (Inst); Alkermes (Inst); Aminex (Inst); Amphivena Therapetics, Inc. (Inst); Biomarin (Inst); Boehringer Ingelheim (Inst); Bristol Myers Squib (Inst); Cerulean Pharma (Inst); Chugai Pharma (Inst); Curis (Inst); Daichi Sanko (Inst); ENB Therapeutics (Inst); Five Prime Therapeutics (Inst); Gene Quantum (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Helix BioPharma (Inst); Incyte (Inst); Jacobio (Inst); Lilly (Inst); MedImmune (Inst); Medivation (Inst); Merck Sharp and Dohme Corp. (Inst); NIH/NCI (Inst); Novartis (Inst); Pfizer (Inst); Pieris Pharmaceuticals (Inst); Principa Biopharma (Inst); Puma Biotechnology (Inst); RAPT Therapeutics (Inst); Seagen (Inst); Silverback Therapeutics (Inst); Taiho Oncology (Inst); Tesaro (Inst); TransThera Biosciences (Inst); XuanZhu (Inst)
 
Vivek Subbiah
Consulting or Advisory Role - Helsinn Therapeutics; Loxo; MedImmune; QED Therapeutics; R-Pharm
Research Funding - Abbvie (Inst); Agensys (Inst); Alfasigma (Inst); Amgen (Inst); Amgen (Inst); Bayer (Inst); Berg Pharma (Inst); Blueprint Medicines (Inst); Boston Biomedical (Inst); D3 Oncology Solutions (Inst); Exelixis (Inst); Fujifilm (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Idera (Inst); Incyte (Inst); Inhibrx (Inst); LOXO (Inst); Multivir (Inst); NanoCarrier (Inst); Northwest Biotherapeutics (Inst); Novartis (Inst); Pfizer (Inst); PharmaMar (Inst); Takeda (Inst); Turning Point Therapeutics (Inst); Vegenics (Inst)
Travel, Accommodations, Expenses - Bayer; Helsinn Therapeutics; Novartis; PharmaMar
Other Relationship - Medscape
 
Apostolia Maria Tsimberidou
Consulting or Advisory Role - Tempus
Research Funding - Agenus (Inst); Boston Biomedical (Inst); IMMATICS (Inst); Karus Therapeutics (Inst); OBI Pharma (Inst); Parker Institute for Cancer Immunotherapy (Inst); Placon (Inst); Stem Cells, Inc. (Inst); Tempus (Inst)
Travel, Accommodations, Expenses - Japanese Society of Clinical Oncology
 
Siqing Fu
Research Funding - Abbisko (Inst); Anaeropharma (Inst); Arrien Pharmaceuticals (Inst); AstraZeneca (Inst); BeiGene (Inst); BioAtla (Inst); Boehringer Ingelheim (Inst); Hookipa Pharma (Inst); Huya Bioscience International (Inst); IMV (Inst); Innovent Biologics (Inst); Lilly (Inst); Lyvgen Biopharma (Inst); MacroGenics (Inst); Medivir (Inst); Millennium (Inst); NCCN (Inst); NCCN (Inst); Nerviano Medical Sciences (Inst); NeuPharma, Inc. (Inst); NIH/NCI (Inst); Novartis (Inst); NovoCure (Inst); OncoMed (Inst); Parexel International, LLC (Inst); Sellas Life Sciences (Inst); Soricimed (Inst); Taiho Oncology (Inst); Tolero Pharmaceuticals (Inst); Turnstone Bio (Inst)
 
Filip Janku
Stock and Other Ownership Interests - Trovagene
Consulting or Advisory Role - Deciphera; Foundation Medicine; Guardant Health; IDEAYA Biosciences; IFM Therapeutics; Immunomet; Jazz Pharmaceuticals; Novartis; PureTech; Sequenom; Sotio; Synlogic; Trovagene; Valeant/Dendreon
Research Funding - Agios (Inst); Asana Biosciences (Inst); Astellas Pharma (Inst); Astex Pharmaceuticals (Inst); BioMed Valley Discoveries (Inst); Bristol-Myers Squibb (Inst); Bristol-Myers Squibb (Inst); Deciphera (Inst); Fujifilm (Inst); Genentech (Inst); Novartis (Inst); Piqur (Inst); Plexxikon (Inst); Proximagen (Inst); Roche (Inst); Symphogen (Inst)
Other Relationship - Bio-Rad
 
Sandra Montez
Speakers' Bureau - Bayer
Research Funding - Ipsen (Inst)
 
Majd T Ahmad-Taha
Research Funding - Ipsen (Inst)
 
Darlene Guerrero
Research Funding - Ipsen (Inst)
 
Natalya N. Nazarenko
Employment - Ipsen; Seagen
Stock and Other Ownership Interests - Seagen
 
Yan Moore
Employment - Ipsen
Leadership - Ipsen
Stock and Other Ownership Interests - Ipsen
 
Michael Soth
Research Funding - Ipsen (Inst)
Patents, Royalties, Other Intellectual Property - I am a co-inventor on patents with MD Anderson, some of which have been licensed to Ipsen. There are potential royalty payments to MD Anderson and I am eligible for revenue sharing.
 
Jeff Kovacs
Research Funding - Ipsen
Patents, Royalties, Other Intellectual Property - Ipsen Pharmaceuticals - IPN60090/IACS-6274 was licensed from MD Anderson Cancer Center by Ipsen as part of a global licensing and joint development agreement. I am a co-inventor on material and method of use patent applications related to IPN60090/IACS-62
 
Timothy P. Heffernan
Stock and Other Ownership Interests - Cullgen; Silicon Therapeutics
Honoraria - Tango Therapeutics
Consulting or Advisory Role - Cullgen; Silicon Therapeutics
Research Funding - Boehringer Ingelheim (Inst); Taiho Pharmaceutical (Inst)
Patents, Royalties, Other Intellectual Property - I am a con-inventor on material and method of use patents for therapeutics developed within MD Anderson. I may personnaly benefit from milestone and royalty agreements through MDA alliances and outlicense agreements.
Travel, Accommodations, Expenses - Cullgen; Tango Therapeutics
 
Philip Jones
Consulting or Advisory Role - Tvardi Therapeutics
Research Funding - Ipsen (Inst); Magnolia NeuroSciences (Inst); Navire (Inst); vescor (Inst)
Patents, Royalties, Other Intellectual Property - MD Anderson Cancer Center